1. Academic Validation
  2. Peptidic Boronic Acid Plasmodium falciparum SUB1 Inhibitors with Improved Selectivity over Human Proteasome

Peptidic Boronic Acid Plasmodium falciparum SUB1 Inhibitors with Improved Selectivity over Human Proteasome

  • J Med Chem. 2024 Aug 8;67(15):13033-13055. doi: 10.1021/acs.jmedchem.4c01005.
Chrislaine Withers-Martinez 1 Elina Lidumniece 2 Fiona Hackett 1 Christine R Collins 1 Zahie Taha 1 Michael J Blackman 1 3 Aigars Jirgensons 2
Affiliations

Affiliations

  • 1 Malaria Biochemistry Laboratory, The Francis Crick Institute, London NW1 1AT, U.K.
  • 2 Latvian Institute of Organic Synthesis, Riga LV-1006, Latvia.
  • 3 Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, U.K.
Abstract

Plasmodium falciparum subtilisin-like serine Protease 1 (PfSUB1) is essential for egress of invasive merozoite forms of the Parasite, rendering PfSUB1 an attractive antimalarial target. Here, we report studies aimed to improve drug-like properties of peptidic boronic acid PfSUB1 inhibitors including increased lipophilicity and selectivity over human Proteasome (H20S). Structure-activity relationship investigations revealed that lipophilic P3 amino acid side chains as well as N-capping groups were well tolerated in retaining PfSUB1 inhibitory potency. At the P1 position, replacing the methyl group with a carboxyethyl substituent led to boralactone PfSUB1 inhibitors with remarkably improved selectivity over H20S. Combining lipophilic end-capping groups with the boralactone reduced the selectivity over H20S. However, compound 4c still showed >60-fold selectivity versus H20S and low nanomolar PfSUB1 inhibitory potency. Importantly, this compound inhibited the growth of a genetically modified P. falciparum line expressing reduced levels of PfSUB1 13-fold more efficiently compared to a wild-type Parasite line.

Figures
Products